Likes Subject
SBFM's a 2-bit vitamin reseller, scammed it's way Homebrew 01/26/23 8:38 AM
This is and always will be a scam Big Eli 02/26/22 11:13 AM
Not sure why that is, but this was mrpennystocks 01/30/23 1:29 PM
So they didn’t own any on 9/30/22, so penny11 01/30/23 1:12 PM
Proequities, Inc. closes position in US8677814035 / Sunshine mrpennystocks 01/30/23 1:00 PM
Here they come mrpennystocks 01/30/23 1:00 PM
Quarterly is starting to roll in. Fidelity already mrpennystocks 01/30/23 2:11 AM
I wonder if that is a form of mrpennystocks 01/30/23 1:47 AM
https://youtu.be/TVs1Vh24DfI JoeLahr 01/29/23 2:24 PM
If don't recall how much they spent on hssbwwmp 01/28/23 5:28 PM
Imho, Doing another share buy back is unlikely Gdubb 01/28/23 4:54 PM
Except they are likely broke, desperate to stay mrpennystocks 01/28/23 2:39 PM
Another share buyback. SBFM should buyback hssbwwmp 01/28/23 12:34 PM
That’s one of my questions. Nora acquisition, plus mrpennystocks 01/28/23 5:29 AM
I have more money invested than than index Gdubb 01/28/23 2:04 AM
Not one institutional investor has a profit except mrpennystocks 01/27/23 7:50 PM
FNCMX - Fidelity Nasdaq Composite Index Fund ownership mrpennystocks 01/27/23 7:26 PM
Not really a good sign to be closing mrpennystocks 01/27/23 6:40 PM
SBFM's a 2-bit vitamin reseller, scammed it's way Homebrew 01/26/23 8:38 AM
When all this happened and so many investors mrpennystocks 01/26/23 8:20 AM
There’s a huge problem with these three things mrpennystocks 01/25/23 11:05 PM
I averaged down 5 times post split and Gdubb 01/25/23 8:13 PM
I guess my question was answered. I mean mrpennystocks 01/25/23 6:54 PM
All we can do is hope now.. most Gdubb 01/25/23 6:40 PM
Because the market doesn't believe they have anything.
Bullish
Bullish
Jean Naymar 01/25/23 5:46 PM
Yes Jean Naymar 01/25/23 5:38 PM
What is the share buy back for? Just to mrpennystocks 01/25/23 4:51 PM
Why isn’t it $2, $5 or $10 and beyond? mrpennystocks 01/25/23 3:42 PM
A red day? What is it 0.01 Jean Naymar 01/25/23 3:22 PM
Another red day after a PR and share mrpennystocks 01/25/23 3:07 PM
Normally a company issues a share buy back mrpennystocks 01/22/23 3:44 PM
The Inflation Reduction Act provision levies a 1% mrpennystocks 01/20/23 9:38 AM
in this period staying in titles like this cary73 01/20/23 2:21 AM
There were very large sell offs within the mrpennystocks 01/20/23 1:33 AM
That is how to day trade! Congrats mrpennystocks 01/19/23 5:34 PM
I came out with a nice profit bought cary73 01/19/23 2:22 PM
You'd think such news of a share buy mrpennystocks 01/19/23 12:58 PM
Sunshine Biopharma Announces Share Repurchase Program aldo 01/19/23 8:16 AM
What are your thoughts? mrpennystocks 01/19/23 2:43 AM
Any comments good or bad? You have penny11 01/18/23 9:32 PM
Ticking sounds SBFM Mt. Blanc 01/18/23 4:42 PM
Someones LOADING UP … Wonder if something has GMJDubbs 01/18/23 3:12 PM
What happened to the mice TRUSTUNITS1000000 01/18/23 11:34 AM
Shareholders post TRUSTUNITS1000000 01/18/23 11:33 AM
Reversal and wonder how long, TRUSTUNITS1000000 01/18/23 11:33 AM
One day someone sells and the next day TRUSTUNITS1000000 01/15/23 1:05 PM
Maybe happy buyers under .70 TRUSTUNITS1000000 01/15/23 1:05 PM
Thanks, I wasn't aware that you had the mrpennystocks 01/13/23 2:05 PM
Did you also read that "they have enough cary73 01/13/23 1:55 AM
The next financial report should have an update mrpennystocks 01/12/23 11:12 PM
[pre] Insider Avg Profit (%) mrpennystocks 01/12/23 4:14 PM
Interesting day! Insiders hold over 10,000,000 shares or mrpennystocks 01/12/23 3:52 PM
Likes Subject

Big Eli
02/26/22 11:13 AM
mrpennystocks
01/30/23 1:29 PM
penny11
01/30/23 1:12 PM
mrpennystocks
01/30/23 1:00 PM
mrpennystocks
01/30/23 1:47 AM
JoeLahr
01/29/23 2:24 PM
hssbwwmp
01/28/23 5:28 PM
mrpennystocks
01/28/23 2:39 PM
hssbwwmp
01/28/23 12:34 PM
mrpennystocks
01/27/23 6:40 PM
mrpennystocks
01/26/23 8:20 AM
mrpennystocks
01/25/23 11:05 PM
mrpennystocks
01/25/23 6:54 PM
Gdubb
01/25/23 6:40 PM
Jean Naymar
01/25/23 5:38 PM
Yes
mrpennystocks
01/25/23 4:51 PM
mrpennystocks
01/25/23 3:42 PM
Jean Naymar
01/25/23 3:22 PM
mrpennystocks
01/25/23 3:07 PM
mrpennystocks
01/22/23 3:44 PM
mrpennystocks
01/20/23 9:38 AM
mrpennystocks
01/20/23 1:33 AM
mrpennystocks
01/19/23 5:34 PM
cary73
01/19/23 2:22 PM
mrpennystocks
01/19/23 12:58 PM
mrpennystocks
01/19/23 2:43 AM
penny11
01/18/23 9:32 PM
Mt. Blanc
01/18/23 4:42 PM
TRUSTUNITS1000000
01/18/23 11:34 AM
TRUSTUNITS1000000
01/18/23 11:33 AM
TRUSTUNITS1000000
01/18/23 11:33 AM
TRUSTUNITS1000000
01/15/23 1:05 PM
TRUSTUNITS1000000
01/15/23 1:05 PM
mrpennystocks
01/13/23 2:05 PM
mrpennystocks
01/12/23 11:12 PM
mrpennystocks
01/12/23 4:14 PM

Sunshine Biopharma Inc (SBFM)

Followers
775
Posters
Posts (Today)
6
Posts (Total)
112549
Created
10/27/08
Type
Free
Moderators JoeLahr Homebrew mrpennystocks
SEC Charges Former CEO of Biotech Company CytoDyn with Fraud, Insider Trading: https://www.sec.gov/news/press-release/2022-232
Is SBFM next for making similar claims? SBFM uplisted around $9 and dropped to $0.62 cents in a matter of months and received a delisting notification warning from NASDAQ.

 


SUNSHINE BIOPHARMA INC
ANTI CANCER DRUGS
ANTI CORONA VIRUS RESEARCH








FORM 4 AWARDED TO CEO FOR CONTRIBUTION AND CREATION OF CORONA

VIRUS TREATMENT PATENT. ( 0.10CENT LIQUIDATION VALUE)
 
 
 





 

































"The Future Of Medicine"
 

http://sunshinebiopharma.com

https://mobile.twitter.com/sunshinepharma_

 
Topoisomerase II is an enzyme that aggressive cancer cells make too much of. When the cell is able to make a lot of the Topoisomerase II 
enzyme, it becomes able to proliferate and metastasize; so, if you can inhibit or destroy the activity of Topoisomerase II, you would then be 
able to prevent cancer cells from spreading. 
 

Our  Proprietary Technology

Our licensor, Advanomics Corporation, has developed a way to replace the diester bond with a Carbon-Difluoride bond which acts as a perfect diester isostere.  This technology allows us to create a large variety of therapeutic compounds that are completely stable and often more active than the original drugs.  This unique capability allowed us to create our Lead Compound, Adva-27a, an effective and highly specific Topoisomerase II (Top2) Inhibitor. 
 




Our Carbon-Difluoride Technology is covered by issued and pending patents filed under PCT/FR2003/002330 and PCT/FR2007/000697
 

Adva-27a is 16-times more effective at killing multidrug resistant  breast cancer cells than Etoposide, the drug currently in use.

Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.

Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies.

Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.

Adva-27a is an excellent inhibitor of Topoisomerase ll with an IC50 of only 13.7 micromolar.


Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats

Adva-27a's initial indication will be multidrug resistant breast cancer for which there are little or no treatment options
 
 
Our Published Data show that Adva-27a is a true Topoisomerase ll Inhibitor and is significantly more effevtive at killing aggressive cancer cells than Etoposide, the current drug of choice.
Unique Features of Adva-27a  

* Adva-27a can be taken orally.
* Adva-27a is not a so-called me-too drug; our technology is unique. Adva-27a will be the only Topoisomerase ll Inhibitor on the Market.
* Adva-27a's initial indication will be multi-drug resistant breast cancer. Adva-27a can be used to treat other Top2 Positive Cancer Types (Prostate, Colon, Lung, Stomach, Ovarian).
Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO, Tel.: 514-814-0464, Camille.sebaaly@sunshinebiopharma.com
 
SBFM SEC Filings

Avastin Ousted By FDA For Breast Cancer, Sunshine Biopharma Gears-Up For Clinicals
 

 
We were incorporated in the State of Colorado on August 31, 2006 under the name “Mountain West Business Solutions, Inc.”  During our fiscal year ended July 31, 2009 our business was to provide management consulting with regard to accounting, computer and general business issues for small and home-office based companies.  Effective October 15, 2009, we executed an agreement to acquire Sunshine Biopharma, Inc., a Colorado corporation (“SBI”), in exchange for the issuance of 21,962,000 shares of our Common Stock and 850,000 shares of Convertible Preferred Stock, each convertible into twenty (20) shares of our Common Stock (the “Agreement”).  As a result of this transaction our officers and directors resigned their positions with us and were replaced by our current management.  Following completion of this transaction we changed our name to “Sunshine Biopharma, Inc.”.  On December 21, 2011, Advanomics Corporation, a privately held Canadian company (“Advanomics”), and our licensor, exercised its right to convert the 850,000 shares of Series “A” Preferred Stock it held in our Company into 17,000,000 shares of Common Stock.
 
Intellectual Property
 
We are the exclusive licensee for the U.S. territory of Advanomics Corporation’s Adva-27a which is covered by international patent applications filed on April 27, 2007 (PCT/FR2007/000697).  These patent applications, which are now issued in Europe and the United States (US 8,236,935) and are still pending elsewhere around the world, were originally owned by Institut National des Sciences Appliquées de Rouen (France) and have recently been purchased by Advanomics Corporation.  On January 14, 2013, Advanomics Corporation filed a new patent application covering Adva-27a manufacturing processes as well as new Adva-27a derivatives and compositions.
 
Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO, Tel.: 514-814-0464, Camille.sebaaly@sunshinebiopharma.com
 

SBFM Transfer Agent
Corporate Stock Transfer
3200 Cherry Creek Dr. South
Suite 430
Denver, CO 80209
(303) 282 - 4800 p
(303) 282 -  5800 f

http://corporatestock.com

                                                          
https://www.sunshinebiopharma.org/
 
New Post